非小细胞肺癌治疗展望.pptVIP

* * * * * * * The addition of TG4010 to fi rst-line chemotherapy for NSCLC is feasible. Several efficacy metrics show a better outcome when the cancer vaccine is added, supporting the hypothesis of synergy between immunotherapy and chemotherapy. Outcome is particularly improved by the addition of TG4010 when the following biomarkers are normal at baseline: triple-positive CD16+CD56+CD69+ lymphocytes, plasma content in soluble CD54, macrophage colony stimulating factor, and interleukin 6. This suggests that the expected therapeutic effect of TG4010 is conditioned by the patient’s immune or infl